Balefire LLC Has $3.83 Million Holdings in Avantor, Inc. (NYSE:AVTR)

Balefire LLC grew its position in Avantor, Inc. (NYSE:AVTR) by 50.8% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 236,379 shares of the company’s stock after purchasing an additional 79,612 shares during the period. Avantor makes up approximately 1.3% of Balefire LLC’s investment portfolio, making the stock its 17th largest holding. Balefire LLC’s holdings in Avantor were worth $3,832,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Tidal Investments LLC increased its stake in Avantor by 59.6% in the 4th quarter. Tidal Investments LLC now owns 18,869 shares of the company’s stock valued at $398,000 after buying an additional 7,048 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Avantor by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,027,636 shares of the company’s stock valued at $63,792,000 after acquiring an additional 74,735 shares in the last quarter. Rhenman & Partners Asset Management AB grew its holdings in shares of Avantor by 40.5% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 61,826 shares of the company’s stock valued at $1,303,000 after acquiring an additional 17,826 shares in the last quarter. Smartleaf Asset Management LLC raised its holdings in Avantor by 106.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,611 shares of the company’s stock worth $34,000 after acquiring an additional 830 shares in the last quarter. Finally, Robeco Schweiz AG raised its holdings in Avantor by 12.5% during the fourth quarter. Robeco Schweiz AG now owns 7,612,555 shares of the company’s stock worth $160,397,000 after acquiring an additional 848,814 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Avantor

In other Avantor news, Director Gregory L. Summe acquired 25,000 shares of the business’s stock in a transaction on Wednesday, May 7th. The stock was purchased at an average price of $12.00 per share, with a total value of $300,000.00. Following the acquisition, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $600,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph R. Massaro bought 8,100 shares of the stock in a transaction dated Tuesday, April 29th. The shares were acquired at an average cost of $12.30 per share, for a total transaction of $99,630.00. Following the completion of the acquisition, the director now directly owns 35,038 shares of the company’s stock, valued at approximately $430,967.40. This trade represents a 30.07% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,100 shares of company stock valued at $1,027,630 in the last ninety days. 1.20% of the stock is currently owned by corporate insiders.

Avantor Stock Up 1.1%

Shares of AVTR opened at $13.61 on Thursday. The firm has a market cap of $9.27 billion, a P/E ratio of 13.09, a price-to-earnings-growth ratio of 1.35 and a beta of 1.04. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.75 and a current ratio of 1.12. Avantor, Inc. has a 52 week low of $11.82 and a 52 week high of $28.00. The firm’s 50-day simple moving average is $13.29 and its 200 day simple moving average is $17.02.

Avantor (NYSE:AVTR) last posted its earnings results on Friday, April 25th. The company reported $0.23 EPS for the quarter, meeting the consensus estimate of $0.23. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a return on equity of 11.93% and a net margin of 10.70%. The firm’s revenue for the quarter was down 5.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.22 earnings per share. On average, analysts forecast that Avantor, Inc. will post 1.06 earnings per share for the current year.

Wall Street Analyst Weigh In

AVTR has been the topic of several recent analyst reports. Wells Fargo & Company lowered their price target on Avantor from $25.00 to $22.00 and set an “overweight” rating on the stock in a research report on Thursday, April 17th. Citigroup decreased their target price on shares of Avantor from $22.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Barclays dropped their price target on shares of Avantor from $18.00 to $15.00 and set an “overweight” rating on the stock in a research report on Monday, April 28th. TD Cowen downgraded shares of Avantor from a “buy” rating to a “hold” rating and set a $15.50 price objective for the company. in a research report on Monday, April 28th. Finally, Robert W. Baird lowered their price objective on shares of Avantor from $21.00 to $17.00 and set an “outperform” rating on the stock in a research note on Monday, April 28th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $18.88.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.